Abstract:Epilepsy is a common disorder of the Central Nervous System. Although several drugs are available for treatment of epilepsy, none of them are applicable for all cases, and some have serious adverse affects. The rational design of small molecule drugs for disorders of the Central Nervous System is a difficult process because the majority of small molecules are unable to cross the Blood- Brain-Barrier. Although many methods have been developed for computer aided drug design, only a few of these are focused on the specific requirements of Central Nervous System drugs. To address these limitations, a validated free and open source drug design package, Autogrow4, was modified to guide the evolution of the population, for generation of molecules with improved permeability across the Blood-Brain-Barrier. This method has the potential for application in computer aided drug design for other Central Nervous System disorders such as Addiction, Alzheimer’s disease, Bipolar disorder, Depression, Gliomas, and Tuberculous meningitis. This method was applied for the design of inhibitors of g-Amino Butyric Acid Transaminase, which is a validated target for the treatment of epilepsy. The ligands designed with this method were predicted to have high binding affinity for the target as well as high permeability across the Blood-Brain-Barrier. The designed molecules were assessed by using the SWISS-ADME webserver which predicted that the designed molecules were Blood-Brain-Barrier permeable, did not have any violation of Lipinsky’s rules and were chemically synthesizable.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to design small - molecule drugs that can effectively penetrate the blood - brain barrier (BBB) to treat epilepsy. Specifically, the authors used an improved evolutionary algorithm to generate molecules with high binding affinity and high BBB permeability, which can be used as effective inhibitors of gamma - aminobutyric acid transaminase (GABA - T). GABA - T is a validated target for treating epilepsy, but the only currently approved drug for this target, Vigabatrin, has serious adverse reactions. Therefore, the development of new GABA - T inhibitors with fewer side effects has important clinical significance. ### Main problems and solutions 1. **Problems**: - **Limitations of existing drugs**: Although there are a large variety of existing anti - epilepsy drugs, not all patients are suitable for them, and some drugs have serious side effects. - **BBB permeability**: Most small - molecule drugs cannot effectively cross the blood - brain barrier, which limits their application in central nervous system (CNS) diseases. 2. **Solutions**: - **Improved evolutionary algorithm**: The authors modified the existing drug - design software Autogrow4 and introduced a new fitness function. This function takes into account not only the binding affinity of the molecule to the target protein (measured by the Vina score) but also the BBB permeability of the molecule (measured by the predicted LogBB value). This improved algorithm is called STgrow4. - **LogBB prediction model**: The authors constructed two partial least - squares regression (PLS - regression) models to predict the LogBB value of molecules. One model is suitable for molecules with non - zero TPSA, and the other model is suitable for molecules with zero TPSA. - **Molecular design and evaluation**: A series of molecules were generated using STgrow4, and the BBB permeability, compliance with the Lipinski rules, and chemical synthesis feasibility of these molecules were evaluated by the Swiss - ADME server. ### Results - **Balance between binding affinity and BBB permeability**: The molecules generated by STgrow4 achieved a better balance between binding affinity and BBB permeability. In particular, when the weight parameter \( W \) was set to 1.5, the generated molecules performed best in terms of binding affinity and BBB permeability. - **Design of specific molecules**: The authors selected five molecules for detailed analysis. These molecules have high binding affinity (low Vina score), good BBB permeability (high LogBB value), and high chemical synthesis feasibility (low Synthetic Accessibility score). ### Discussion - **Clinical significance**: The development of new GABA - T inhibitors is expected to improve the treatment effect of epilepsy and reduce side effects. - **Advantages of the method**: STgrow4 improves the quality of generated molecules and reduces the burden of later screening by simultaneously optimizing binding affinity and BBB permeability during the evolution process. - **Future directions**: This method can be further applied to drug design for other CNS diseases, such as addiction, Alzheimer's disease, bipolar disorder, depression, glioma, and tuberculous meningitis. In conclusion, this paper successfully designed a series of GABA - T inhibitors with high binding affinity and high BBB permeability through an improved evolutionary algorithm and LogBB prediction model, providing new candidate drugs for the treatment of epilepsy.

Computational design of drugs for Epilepsy using a novel guided evolutionary algorithm for enhanced Blood Brain Barrier permeability

Multi-objective generative AI for designing novel brain-targeting small molecules

The Drug Design and Discovery of Novel Enaminone Derivatives as Potential Anti-seizure Agents

NeuroCADR: Drug Repurposing to Reveal Novel Anti-Epileptic Drug Candidates Through an Integrated Computational Approach

Drug Repurposing Pipeline for Epilepsy: Integrating Deep Learning and Structure-based Approaches

A systems-level framework for anti-epilepsy drug discovery

Uterus retrieval in cadaver: technical aspects.

In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy

ROS-removing Nano-Medicine for Navigating Inflammatory Microenvironment to Enhance Anti-Epileptic Therapy

Analysis and Construction of a Molecular Diagnosis Model of Drug-Resistant Epilepsy Based on Bioinformatics

Design, synthesis, biological evaluation, homology modeling and docking studies of (E)-3-(benzo[d][1,3]dioxol-5-ylmethylene) pyrrolidin-2-one derivatives as potent anticonvulsant agents

ML-Based Models as a Strategy to Discover Novel Antiepileptic Drugs Targeting Sodium Receptor Channel

Intracellular Metabotropic Glutamate Receptor 5 (mGluR5) Activates Signaling Cascades Distinct from Cell Surface Counterparts*

Infections associated with long-term prosthetic devices.

Nanoengineered on-demand drug delivery system improves efficacy of pharmacotherapy for epilepsy

Development of a novel glucose‐dendrimer based therapeutic targeting hyperexcitable neurons in neurological disorders

Discovery of Novel Isonipecotic Acid-Based Heteroaryl Amino Acid Derivatives as Potential Anticonvulsant Agents: Design, Synthesis, In-Silico ADME Study, and Molecular Docking Studies

Integrated workflow for the identification of new GABAA R positive allosteric modulators based on the in silico screening with further in vitro validation. Case study using Enamine's stock chemical space

Design, synthesis, and development of novel caprolactam anticonvulsants

The In Vitro Invasion Inhibition Assay (IIA) for Plasmodium vivax.

Searching for New Leads To Treat Epilepsy: Target-Based Virtual Screening for the Discovery of Anticonvulsant Agents